Abstract A125: External Control Arms: a vital strategy to create high quality scientific evidence with patient centric trial design for pancreatic cancer trials in light of introduction of highly effective targeted therapies
Abstract
AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development The evolution of targeted therapies in pancreatic ductal adenocarcinoma (PDAC) may pose challenges for future clinical research. Assigning patients to standard-of-care chemotherapies in randomized controlled trials (RCTs) may become ethically complex and practically infeasible, slowing drug development for this high-unmet-need population, if targeted therapies are available. This session will demonstrate how external control arms (ECAs), using patient-level data from prior trials or real-world sources, can:1. Create more patient-centric, operationally-feasible, late-phase RCTs that increase the chances of trial patients being randomized to new therapies while maintaining scientific credibility.2. Provide important contextual evidence to improve scientific certainty in early-phase trials.Key Use Cases Include:1. A multi-stakeholder validation pilot with Friends of Cancer Research to determine if an ECA can replicate overall survival (OS) outcomes from a historical PDAC trial’s randomized control arm.2. Contextualization of an early-phase, uncontrolled trial’s efficacy outcomes to inform internal decision-making and generate early comparative evidence. We present findings evaluating ECA alignment to a randomized control in a Friends of Cancer Research pilot. Results highlight that with high-quality data and careful propensity score matching or weighting, external controls can replicate a randomized control. We also present the results of an ECA used to contextualize efficacy outcomes in a phase 1b uncontrolled trial. External controls represent a necessary shift in PDAC research. By providing alternatives to 1:1 randomized trials and gaining more insights from early-phase, single-arm trials, ECAs facilitate scientific progress and reduce patient burden. The work presented here underscores that with rigorous methodology and fit-for-purpose data, adopting these innovative designs is essential for maintaining momentum in pancreatic cancer research, ultimately delivering life-saving treatments faster. The text for this abstract was generated with the assistance of an AI tool. Ruthie Davi. External Control Arms: a vital strategy to create high quality scientific evidence with patient centric trial design for pancreatic cancer trials in light of introduction of highly effective targeted therapies [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr A125.